AQP4	Aquaporin-4
CXCL13	C-X-C Motif chemokine ligament
CHI3L1	Chitinase-3-like-1
CDMS	Clinically definitive MS
CIS	Clinically isolated syndrome
COI	Cost of illness
DMT	Disease-modifying therapy
DMA	Disease-modifying agents
DMDs	Disease-modifying drugs
DILI	Drug-induced liver damage
EDSS	Expanded disability status scale
EMA	European medicine agency
EBA	Epstein-Barr virus
GDP	Gross domestic product
GFAB	Glial Fibrillary acidic protein
GA	Glatiramer acetate
HLA	Human leukocyte antigen
HHV-6	Human herpes virus-6
ILs	Interleukins
IFN-γ	Interferon-gamma
IRDA	Insurance regulatory anddevelopment authority of India
iNOS	Inducible-type nitric oxide
IF	Intermediate filament
IBD	Inflammatory bowel disease
MS	Multiple sclerosis
MRI	Magnetic resonance imaging
MHC	Major histocompatibility complex
MOG	Myelin oligodendrocytes
MAGNIMS	Magnetic resonance imaging in MS
NEDA	No evidence of disease activity
NMOSD	Neuromyelitisoptica spectrum disease
NMO	Neuromyelitis optica
NR	Neurology resident
NO	Nitric oxide
NFL	Neurofilament light chain
ONTT	Optic neuritis
OCB	Oligoclonal bands
OCGB	Patched
ON	Optic neuritis
OCT	Optical coherence tomography
PPMS	Primary progressive MS
PET	positron emission tomography
RRMS	Relapsing-remitting MS
RIS	Radiologically isolated syndrome
SPMS	Secondary progressive MS
SNPs	Single-nucleotide polymorphism
TNF-α	Tumor necrosis factor-alpha
Th	T-helper cell
WHO	World Health Organization